Novo Nordisk joins Evotec as drug discover...Novo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets. more ➔
Genkyotex cashes in €7.5mFrench Genkyotex SA has secured an €7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis (PBC). more ➔
Roche’s Alecensa approved in ChinaRoche AG’s ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung … more ➔
Pfizer partners with Biontech in US$425m d... BioNTech AG has partnered with Pfizer to develop a mRNA-based flu vaccine. more ➔
New lupus target unraveledEGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and … more ➔
Small molecule restores liver regenerationA team of Scots, Belgian and Spanish researchers claim they have found a target to prevent failure of liver regeneration following intoxination or acute injury. more ➔
Orchard Therapeutics raise US-$150mLondon-headquartered gene therapy Orchard Therapeutics has closed a US-$150m series C financing round to push MAAs and BLAs of three late-stage gene therapies by 2021. more ➔
Artios Pharma raise €85m in Series B rou...Life Sciences Partners and Andera Partners together with Pfizer Ventures and Novartis Venture Fund have put €85m into the cancer drug development company Artios Pharma Ltd. more ➔
Researchers remyelinate neuronsGerman neurogenetics at the Max-Planck-Institute for Experimental Medicine have cured the rare incurable hereditary Charcot-Marie-Tooth disease by simply supplementing the food of mice carrying … more ➔
Switch for osteoporosis and obesityGerman researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes. … more ➔
